VK2735

Last updated

VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. It is injectable and is being developed by Viking Therapeutics. [1] [2] [3]

References

  1. ↑ Mariam E Sunny, Bhanvi Satija (2024-02-27). "Viking Therapeutics notches success with weight-loss drug trial, shares double". Reuters. Retrieved 2024-03-09.
  2. ↑ Goldenberg, Ronald M.; Teoh, Hwee; Verma, Subodh (2023-08-21). "Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data". Current Opinion in Cardiology. 38 (6). Ovid Technologies (Wolters Kluwer Health): 539–545. doi:10.1097/hco.0000000000001084. ISSN   0268-4705. PMID   37792556.
  3. ↑ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists". Obesity Reviews. 25 (3) e13663. doi:10.1111/obr.13663. ISSN   1467-7881. PMID   37968541.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.